skip to primary navigationskip to content

Cambridge Infectious Diseases

An Interdisciplinary Research Centre at the University of Cambridge

Studying at Cambridge

 

Dr Claudio Köser

Dr Claudio Köser

Visiting scientist at Department of Genetics. Consultant for the Foundation for Innovative New Diagnostics (FIND), QuantuMDx Group Ltd. and the World Health Organization Regional Office for Europe.

Claudio Köser is available for consultancy.


Departments and Institutes

Genetics:

Research Interests

Development of assays for genotypic and phenotypic drug-susceptibility testing for the Mycobacterium tuberculosis complex

Topics

  • Tuberculosis

Key Publications

Senior scientific analyst. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis [WHO/CDS/TB/2018.5]. World Health Organization. Available from: http://apps.who.int/iris/bitstream/10665/260470/1/WHO-CDS-TB-2018.5-eng.pdf.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01550-17.
What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi- and extensively drug-resistant tuberculosis.
Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M.

Eur Respir J. 2017 Dec 28;50(6). pii: 1701354.
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02169-16.
Some synonymous and nonsynonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-positive fluoroquinolone resistance results with the Hain GenoType MTBDRsl assays.
Ajileye A, Alvarez N, Merker M, Walker TM, Akter S, Brown K, Moradigaravand D, Schön T, Andres S, Schleusener V, Omar SV, Coll F, Huang H, Diel R, Ismail N, Parkhill J, de Jong BC, Peto TE, Crook DW, Niemann S, Robledo J, Smith EG, Peacock SJ, Köser CU.

Lancet. 2015 Jan 24;385(9965):305-7.
Drug-resistance mechanisms and tuberculosis drugs.
Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME.

Trends Genet. 2014 Sep;30(9):401-7.
Whole-genome sequencing to control antimicrobial resistance.
Köser CU, Ellington MJ, Peacock SJ.

N Engl J Med. 2013 Jul 18;369(3):290-2.
Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis.
Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ 

Antimicrob Agents Chemother. 2012 Dec;56(12):6080-7.
Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.
Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S.

PLoS Pathog. 2012 Aug;8(8):e1002824.
Routine use of microbial whole genome sequencing in diagnostic and public health microbiology.
Köser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown NM, Farrington M, Holden MT, Dougan G, Bentley SD, Parkhill J, Peacock SJ.

N Engl J Med. 2012 Jun 14;366(24):2267-75.
Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak.
Köser CU, Holden MT, Ellington MJ, Cartwright EJ, Brown NM, Ogilvy-Stuart AL, Hsu LY, Chewapreecha C, Croucher NJ, Harris SR, Sanders M, Enright MC, Dougan G, Bentley SD, Parkhill J, Fraser LJ, Betley JR, Schulz-Trieglaff OB, Smith GP, Peacock SJ.